← Back to headlines
Eli Lilly sees strong growth from Mounjaro and GLP-1 demand
Eli Lilly (LLY) is experiencing robust growth, primarily driven by the momentum of its drug Mounjaro and increasing demand for GLP-1 medications, leading Barclays to maintain a bullish outlook on the company.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
Related Stories
Strategy Returns to Bitcoin Market With $370 Million Purchase
33m ago
US company to operate Venezuelan oil fields previously controlled by China and Russia
49m ago
IKEA Slashes Prices Across Europe to Attract Budget-Conscious Shoppers
49m ago
Global Bond Selloff Drives Up Treasury Yields Amid Investor Caution
1h ago